Clinical Trial Search

Primary: Percentage Change in EASI (Eczema Area and Severity Index) From Baseline to Week 16 (Part 1) — -61.5; -56.8; -51.6; -59.6 percentage of change — p=<0.0001

Primary: Change in Hand Strength During Intervention and at Follow-up. — 24; 23 KG

Primary: Objective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Per Investigator Assessment — 20.0; 13.9 Percent of participants

Primary: Change in Immunologic Markers Following Combination of Study Drug With Chemoradiation — 31.31; 140.33 ratio of cells per mm^2", "CD8+: FoxP3+

Primary: Cold Temperature Deflection Point — 22.8; 22.97 degrees Celsius

Primary: Cohort 1 and 2: Time to Baseline Monthly Seizure Count up to the End of the 12-week Double-blind (DB) Treatment Period — 32; 34; 29; 38 Days — p=0.3571

Primary: Dose Conversion Factor — 4.24 Ratio

Primary: Changes in Gray Matter Intracranial Pulsatility — -0.09; 0.02 mm/cardiac cycle

Primary: Children's Depression Rating Scale - Revised — 36.0; 37.5 score on a scale — p=0.76

Primary: Brief Pain Inventory Short Form (BPI-SF) Average Interference Score at 12 Weeks of Treatment — 6.30; 5.76 score on a scale — p=0.129

Primary: Cohort A: Objective Response Rate (ORR) — 20.0 percentage of participants

Primary: PET Changes in the Paraventricular Nucleus From Baseline to 26 Weeks. — 0.0350 Binding Potential (non-displaceable)

Primary: Change in the Combined Pulmonary, Cardiovascular, Hematologic, Nervous System, and Renal Subscores of the Snakebite Severity Score (SSS) — 1.1; 1.5 Snakebite Severity…

Primary: Change From Baseline in the Weekly Average of Daily Pain Intensity on a Numeric Pain Rating Scale (NPRS) — -2.09; -2.18; -2.11; -2.26 units on a scale

Primary: Effect on Cerebral Blood Flow in White Matter, Gray Matter, Deep White Matter, Deep Gray Matter, and Thalamus — 8.55; 5.12; 5.78; 2.06 Percentage of change in CBF